RESUMEN
Sunday, day of rest in a pavilion of Seine-Saint-Denis in this so particular period of confinement because of the coronavirus disease 2019. Time seems to stand still. A healthcare executive shares his experiences at the "Les 4 Saisons" accommodation facility for dependent elderly, located in Bagnolet.
Asunto(s)
COVID-19 , Atención a la Salud/organización & administración , Hogares para Ancianos , Casas de Salud , Anciano , Humanos , Pandemias , Ejecutivos Médicos , SARS-CoV-2RESUMEN
SSR125329A ([(Z)-3-(4-Adamantan-2-yl-3,5-dichloro-phenyl)-allyl]-cyclohexyl-ethyl-amine) is a new ligand exhibiting high affinity for sigma(1) and sigma(2) receptors and for the human Delta8-Delta7-sterol isomerase. Here we show that this molecule has potent immunoregulatory properties both in vitro and in vivo. SSR125329A inhibited staphylococcal enterotoxin B-induced mouse splenocyte proliferation in vitro, whereas in vivo it enhanced lipopolysaccharide-induced systemic release of interleukin-10 while simultaneously inhibiting tumor necrosis factor-alpha (TNF-alpha) synthesis. It also prevented graft-versus-host disease in B6D2F1 mice and protected Mrl/lpr mice against the development of its spontaneous rheumatoid-like syndrome. There is high interplay of pro- and anti-inflammatory cytokines in inflammatory processes, particularly in human rheumatoid arthritis. The results of this study provide substantial evidence that sigma receptor ligands may represent a new effective approach for rheumatoid arthritis treatment.